Overalls

Atlas® Van Lines’ Annual Study Highlights Steady Corporate Relocation and Company Growth

Retrieved on: 
Tuesday, March 26, 2024
Professional Services, Trucking, Transport, Logistics, Supply Chain Management, Human Resources, Other Transport, Consumer, Growth, Atlas, Safety, Intelligence, COVID-19, Female, Artificial intelligence, AI, Overalls, Woman, Pew Research Center, Workforce, Pew, Workplace, Investment company, Drug

Atlas’ Corporate Relocation Survey is the industry’s first and longest-running deep dive into corporate relocation policies and practices.

Key Points: 
  • Atlas’ Corporate Relocation Survey is the industry’s first and longest-running deep dive into corporate relocation policies and practices.
  • 1 in 3 companies reported company growth as a factor in relocation, an increase of 5 points from 2022.
  • Company growth was the number one internal factor impacting relocation in 2023, a likely side effect of overall economic improvements during the year.
  • For this year’s complete survey results, visit the Atlas Van Lines Corporate Relocation Survey results online at https://www.atlasvanlines.com/resources/corporate-relocation-survey/2024 .

Holley Performance Brands Appoints Two New Vice Presidents Focused on Accelerating Strategic Growth Across Key Performance Aftermarket Verticals

Retrieved on: 
Tuesday, March 26, 2024
Other Manufacturing, Automotive, General Automotive, Marketing, Automotive Manufacturing, Communications, Manufacturing, Performance & Special Interest, Off-Road Trucks & SUVs, Cloud, Firestone, CRM, Volkswagen Group, Growth, SUV, Safety, Nike, News, Digital, Overalls, Adobe Experience Cloud, Multimedia, Volkswagen Group of America, Risk management

Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced the addition of two new senior leaders who will focus on enhancing the customer experience across Holley’s portfolio of iconic brands.

Key Points: 
  • Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced the addition of two new senior leaders who will focus on enhancing the customer experience across Holley’s portfolio of iconic brands.
  • “Charlie and Will are dynamic leaders with deep understanding of the automotive aftermarket, and we’re confident that their leadership will help us identify new opportunities for growth.
  • As vice president of digital, data and CRM, he will develop and execute strategies aimed at achieving growth through digital channels.
  • “The Holley name is synonymous with performance and the company is known for putting enthusiasts first,” said Robbins.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, Science, Consumer Electronics, Human Genome Project, WGS, Blood pressure, Genomics, Certification, Informatics, Genetic testing, Nucleus, Risk, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1, Vaccine

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

UniCare Health Plan of West Virginia First in the State to Earn NCQA Health Equity Accreditation Plus

Retrieved on: 
Thursday, March 21, 2024
Professional Services, DEI (Diversity, Equity and Inclusion), Health, Health Insurance, Social Services, General Health, Andrew Kohut, Disease, NCQA, Transport, Health equity, Diabetes, Mortality, Gender identity, Overalls, Medicaid, UniCare, Quality assurance, Language, Hypertension, Accreditation, National Committee, Nursing

UniCare Health Plan of West Virginia recently earned the National Committee for Quality Assurance (NCQA) Health Equity Accreditation Plus, a recognition of UniCare’s leadership in developing solutions to enhance access equitable, high-quality healthcare.

Key Points: 
  • UniCare Health Plan of West Virginia recently earned the National Committee for Quality Assurance (NCQA) Health Equity Accreditation Plus, a recognition of UniCare’s leadership in developing solutions to enhance access equitable, high-quality healthcare.
  • “NCQA’s Health Equity Accreditation Plus recognizes our unwavering dedication to eliminating health disparities and ensuring access to high-quality care for everyone,” said Tadd Haynes, President, UniCare Health Plan of West Virginia.
  • “This milestone positions UniCare at the forefront of advancing health equity through our innovative and impactful programs and personalized care to improve the whole health of our members.”
    NCQA Health Equity Accreditation Plus builds upon the Health Equity Accreditation designation UniCare received last year, when it was recognized among the first Medicaid plans in the nation to create a strategic framework that prioritizes health equity based on race, ethnicity, language, sexual orientation, and gender identity.
  • “Organizations earning the Health Equity Accreditation Plus like UniCare Health Plan of West Virginia are leading the way in bridging this gap, and NCQA salutes their commitment.”

World Obesity Drugs and Delivery Platforms Research Report 2023: Pipeline Analysis, Drug Delivery Innovations, Outlook, Acquisitions, Partnerships, and Funding - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
General Health, Biometrics, Health, Fitness & Nutrition, Pharmaceutical, Obesity, Probiotic, Risk, Mineral, Prognosis, Bariatric surgery, Weight loss, BMI, Vitamin, Body mass index, Clinical trial, Mortality, Nutrient, Developed country, Overalls, Fast food

The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering.
  • In this study, the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies are analyzed.
  • The study also provides insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.
  • GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.

Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

Retrieved on: 
Thursday, March 21, 2024
Health, General Health, Research, Attention, Conference, Obesity, Growth, Telephone, Overalls, PMA, Preannouncement, Marketing, FDA, Total, Food, Pharmaceutical industry

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion”), a company dedicated to ending obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance.

Key Points: 
  • Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion”), a company dedicated to ending obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance.
  • “As we begin 2024, this demand has continued to increase, and we have seen improvement in some of the macro conditions that negatively impacted the fourth quarter.
  • Gross profit for the fourth quarter was 78% of revenue, compared to 79% of revenue in the same period in 2022.
  • For full year 2024, Allurion reiterates the financial guidance it previously published:
    Revenue of $60 to $65 million, reflecting 12-22% growth year-over-year
    Allurion management will host a conference call at 8:30 a.m.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Global Shipments of Wearables Devices Saw Modest Growth in 2023 with Improved Demand Expected in 2024 and Beyond, According to IDC

Retrieved on: 
Wednesday, March 20, 2024
Technology, Hardware, Consumer Electronics, Wearables, Mobile Technology, Consumer, Attention, Growth, Meta, Research, International Data Group, IDC, Overalls, Life, Mobility, Video game

However, shipments grew 1.7% in Asia/Pacific and in China largely due to strong interest in emerging markets.

Key Points: 
  • However, shipments grew 1.7% in Asia/Pacific and in China largely due to strong interest in emerging markets.
  • The next two years saw the aftermath of that success as demand began to wane and shipments steadily declined," said Ramon T. Llamas , research director with IDC's Wearables team.
  • While the market declined slightly in 4Q23, global shipments of wearable devices managed to grow 1.7% for the full year 2023.
  • With the global economy on a path to recovery, wearables are poised for additional growth in 2024 as device shipments are forecast reach 559.7 million units, up 10.5% over 2023.

Schellman Welcomes Christopher Kouzios as New CIO, Reinforcing InfoSec Leadership

Retrieved on: 
Tuesday, March 19, 2024
Professional Services, Security, Technology, Other Professional Services, Other Technology, Software, API, Artificial intelligence, Organization, Optum, Integration, Growth, Overalls

Schellman , a leading provider of attestation and compliance services and a top 50 CPA firm, today announced the appointment of Christopher Kouzios as the company's new Chief Information Officer.

Key Points: 
  • Schellman , a leading provider of attestation and compliance services and a top 50 CPA firm, today announced the appointment of Christopher Kouzios as the company's new Chief Information Officer.
  • With his exceptional expertise in information security initiatives, Kouzios is set to spearhead Schellman's technology initiatives including advancing the firm’s Artificial Intelligence endeavors.
  • As the firm is poised to achieve new, extraordinary milestones in the ever-evolving landscape of compliance assessments, Kouzios will steer the firm’s global strategy.
  • "Schellman's dedication to trust and excellence extends to the digital space,” said Kouzios.

Medallia Named a Leader in the 2024 Gartner® Magic Quadrant™ for Voice of the Customer Platforms Report

Retrieved on: 
Tuesday, March 19, 2024
Social Media, Data Management, Technology, Audio, Video, Marketing, Communications, Apps, Applications, Professional Services, Artificial Intelligence, Other Technology, Software, Digital Marketing, Networks, Data Analytics, Internet, Mobile, Wireless, VOC, Organization, Customer retention, Research, CX, Overalls, Human voice, Customer service, Human, Mobile phone

Medallia, Inc. , the global leader in customer and employee experience, today announced that it has been named a Leader for the third consecutive year in the Gartner Magic Quadrant™ for Voice of the Customer (VoC).

Key Points: 
  • Medallia, Inc. , the global leader in customer and employee experience, today announced that it has been named a Leader for the third consecutive year in the Gartner Magic Quadrant™ for Voice of the Customer (VoC).
  • Medallia was named a leader for its Ability To Execute’ and Completeness Of Vision.
  • “Medallia is so proud to be named a leader in the Gartner Magic Quadrant™ for Voice of Customer,” said Joe Tyrrell, CEO at Medallia.
  • Magic Quadrants position vendors in a market, while Critical Capabilities provides a deeper dive into the providers’ product and service offerings.